This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
by Sundeep Ganoria
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
NVSNegative Net Change BMYNegative Net Change VRTXPositive Net Change BEAMPositive Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy genomics medical pharmaceuticals
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
GSKNegative Net Change NVONegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
LLYPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change VERVPositive Net Change
biotechnology biotechs gene-editing medical pharmaceuticals
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
by Zacks Equity Research
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
BIIBNegative Net Change SUPNNegative Net Change SAGEPositive Net Change
biotechs
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
by Zacks Equity Research
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
SNYNegative Net Change BMYNegative Net Change LLYPositive Net Change VERVPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
by Zacks Equity Research
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
BAYRYNegative Net Change QGENNegative Net Change INCYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
by Zacks Equity Research
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
TEVANegative Net Change BAYRYNegative Net Change AGENPositive Net Change IMCRPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
by Zacks Equity Research
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
RHHBYNegative Net Change ABBVNegative Net Change AGENPositive Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
by Zacks Equity Research
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
GRFSNegative Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
by Zacks Equity Research
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
GSKNegative Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
by Zacks Equity Research
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
NVSNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change PRTAPositive Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
by Zacks Equity Research
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
RHHBYNegative Net Change SRPTPositive Net Change AGENPositive Net Change IMCRPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
by Ekta Bagri
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
BMYNegative Net Change MRKNegative Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
by Zacks Equity Research
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
NVSNegative Net Change NVONegative Net Change LLYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
NVSNegative Net Change BMYNegative Net Change BAYRYNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
SNYNegative Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Insmed Stock Jumps 29% on Encouraging PAH Study Results
by Zacks Equity Research
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
UTHRNegative Net Change INSMNegative Net Change LQDAPositive Net Change
biotechs medical
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
by Zacks Equity Research
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
GSKNegative Net Change NVSNegative Net Change GILDPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
SNYNegative Net Change AZNNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechs medical pharmaceuticals vaccines
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
AZNNegative Net Change NVSNegative Net Change BMYNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change FATENo Net Change
biotechs cancer pharmaceuticals
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
by Zacks Equity Research
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
ALNYPositive Net Change BAYRYNegative Net Change LXRXNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
JNJPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals